Our Team

Sarb Shergill has over 30 years of experience in drug development. Most recently, she was Corporate Vice President of Boston Global Development at Novo Nordisk, leading programs in rare diseases and cardio-metabolic disorders.

Prior to Novo Nordisk, Dr. Shergill was SVP Clinical Operations and Data Management at ResTORbio Inc., a company focused on the development of drugs for the treatment of diseases related to aging.

Previously, Dr. Shergill was VP Clinical Operations and Data Management at Akebia Therapeutics, where she was responsible for leading the Phase 3 cardiac outcomes program in renal anemia. She also worked at Sanofi following the acquisition of Genzyme Corporation. At Genzyme, she held positions of increasing responsibility and seniority, working in several therapeutic areas including rare diseases, CNS, oncology, cardiovascular, and renal. Dr. Shergill has a Ph.D. in Pharmacology from Liverpool John Moores University in the UK.